FDA guidance
S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals
FDA guidance · Final · issued Sep 17, 2008
Key facts
| Title | S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals |
|---|---|
| Status | Final |
| Issue date | Sep 17, 2008 |
| Center | Center for Drug Evaluation and Research |
| Issuing office | Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Drugs |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents